Comparative effectiveness research in follicular lymphoma: Current and future perspectives and challenges

Journal of Comparative Effectiveness Research

Volumn 3, Issue 1, 2014, Pages 95-107

  Wudhikarn, Kitsada ^a   Link, Brian K ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

comparative effectiveness research; follicular lymphoma

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL RESEARCH; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FOLLICULAR LYMPHOMA; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MEDICARE; NONHODGKIN LYMPHOMA; NORTH AMERICA; OBSERVATIONAL STUDY; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REGISTER; REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC);

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; COMBINED MODALITY THERAPY; COMPARATIVE EFFECTIVENESS RESEARCH; HUMANS; IMMUNOTHERAPY; LYMPHATIC IRRADIATION; LYMPHOMA, FOLLICULAR; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; REMISSION INDUCTION; RESEARCH DESIGN; SEER PROGRAM; WATCHFUL WAITING;

EID: 84890914035     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.13.86     Document Type: Review

References (72)

1. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann. Intern. Med. 151, 203-205 (2009).
2. Iglehart JK. Prioritizing comparative-effectiveness research -IOM recommendations. N. Engl. J. Med. 361, 325-328 (2009).
3. Lauer MS, Collins FS. Using science to improve the nation's health system: NIH's commitment to comparative effectiveness research. JAMA 303, 2182-2183 (2010).
4. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106, 3725-3732 (2005).
5. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105, 1417-1423 (2005).
6. Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, Phase 3 non-inferiority trial. Lancet 381, 1203-1210 (2013).
7. Feudtner C, Schreiner M, Lantos JD. Risks (and benefits) in comparative effectiveness research trials. N. Engl. J. Med. 369, 892-894 (2013).
8. Vist GE, Bryant D, Somerville L et al. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst. Rev. 2, MR000009 (2008).
9. Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a Phase 3, randomised controlled trial. Lancet 377, 42-51 (2011).
10. Lyman GH. Comparative effectiveness research in oncology. Oncologist 18(6), 752-759 (2013).
11. Armstrong K. Methods in comparative effectiveness research. J. Clin. Oncol. 30, 4208-4214 (2012).
12. Morton LM, Wang SS, Devesa SS et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107, 265-276 (2006).
13. Conconi A, Motta M, Bertoni F et al. Patterns of survival of follicular lymphomas at a single institution through three decades. Leuk. Lymphoma 51, 1028-1034 (2010).
14. Tan D, Horning SJ, Hoppe RT et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma over four decades: the Stanford University experience. Blood 122(6), 981-987 (2013).
15. Leich E, Ott G, Rosenwald A. Pathology, pathogenesis and molecular genetics of follicular NHL. Best Pract. Res. Clin. Haematol. 24, 95-109 (2011).
16. Friedberg JW, Taylor MD, Cerhan JR et al. Follicular lymphoma in the United States: first report of the National LymphoCare Study. J. Clin. Oncol. 27, 1202-1208 (2009).
17. Simonds NI, Khoury MJ, Schully SD et al. Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J. Natl Cancer Inst. 105, 929-936 (2013).
18. Amador-Ortiz C, Chen L, Hassan A et al. Combined core needle biopsy and fine-needle aspiration with ancillary studies correlate highly with traditional techniques in the diagnosis of nodal-based lymphoma. Am. J. Clin. Pathol. 135, 516-524 (2011).
19. Ghesquieres H, Cartron G, Seymour JF et al. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 120, 2650-2657 (2012).
20. Charbonneau B, Maurer MJ, Fredericksen ZS et al. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am. J. Hematol. 87, 880-885 (2012).
21. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003).
22. Wang SS, Maurer MJ, Morton LM et al. Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 23, 596-602 (2009).
23. Han X, Zheng T, Foss FM et al. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am. J. Hematol. 85, 51-56 (2010).
24. Wudhikarn K, Button AM, Smith BJ et al. Correlation of chemotherapy delivery and survival outcomes of follicular lymphoma in the immunochemotherapy era. J. Clin. Oncol. 31 (2013).
25. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 110, 3507-3516 (2007).
26. Abou-Nassar KE, Vanderplas A, Friedberg JW et al. Patterns of use of 18-fluoro-2-deoxy-d-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leuk. Lymphoma 54(10), 2155-2162 (2013)/
27. Luminari S, Biasoli I, Arcaini L et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann. Oncol. 24(8), 2108-2112 (2013).
28. Trotman J, Fournier M, Lamy T et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J. Clin. Oncol. 29, 3194-3200 (2011).
29. Schöder H, Noy A, Gönen M et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 4643-4651 (2005).
30. Amir E, Seruga B, Kwong R, Tannock IF, Ocaña A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur. J. Cancer 48(3), 385-388 (2012).
31. Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol. 26, 4579-4586 (2008).
32. Zinzani PL, Pulsoni A, Perrotti A et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J. Clin. Oncol. 22, 2654-2661 (2004).
33. Flinn IW, van der Jagt RH, Kahl BS et al. An Open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): the BRIGHT study. Blood 120(21), Abstract 902 (2012).
34. Federico M, Luminari S, Dondi A et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J. Clin. Oncol. 31, 1506-1513 (2013).
35. Sebban C, Mounier N, Brousse N et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108, 2540-2544 (2006).
36. Deconinck E, Foussard C, Milpied N et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105, 3817-3823 (2005).
37. Ardeshna K, Qian W, Smith P et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2, and 3a). A preliminary analysis. Blood 116(21), Abstract 6 (2010).
38. Griffiths RI, Gleeson ML, Mikhael J, Danese MD. Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare. J. Cancer Epidemiol. 2012, 978391 (2012).
39. Griffiths RI, Gleeson ML, Mikhael J et al. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer 118, 6079-6088 (2012).
40. Al Khabori M, de Almeida JR, Guyatt GH et al. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 104, 18-28 (2012).
41. Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Cochrane Database Syst. Rev. 1, CD007678 (2012).
42. Rohatiner AZ, Johnson PW, Price CG et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J. Clin. Oncol. 12, 1177-1184 (1994).
43. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 2453-2463 (2002).
44. Fowler N, Kahl BS, Lee P et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the Phase II VERTICAL study. J. Clin. Oncol. 29, 3389-3395 (2011).
45. Coiffier B, Osmanov EA, Hong X et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised Phase 3 trial. Lancet Oncol. 12, 773-784 (2011).
46. Friedberg JW, Vose JM, Kelly JL et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117, 2807-2812 (2011).
47. van Oers MH, Van Glabbeke M, Giurgea L et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 Phase III randomized intergroup study. J. Clin. Oncol. 28, 2853-2858 (2010).
48. Robinson SP, Canals C, Luang JJ et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 48(11), 1409-1414 (2013).
49. Kahl BS, Hong F, Williams ME et al. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood 118(21), Abstract LBA-6 (2011).
50. Zelenetz AD, Wierda WG, Abramson JS et al. Non-Hodgkin's lymphomas, version 3.2012. J. Natl Compr. Cancer Netw. 10, 1487-1498 (2012).
51. McNamara C, Davies J, Dyer M et al. Guidelines on the investigation and management of follicular lymphoma. Br. J. Haematol. 156, 446-467 (2012).
52. Malone J, Guleria R, Craven C et al. Justification of diagnostic medical exposures: some practical issues. Report of an International Atomic Energy Agency Consultation. Br. J. Radiol. 85, 523-538 (2012).
53. Bodet-Milin C, Eugene T, Gastinne T et al. FDG-PET in follicular lymphoma management. J. Oncol. 2012, 370272 (2012).
54. Thompson CA, Maurer MJ, Ghesquieres H et al. Utility of post-therapy surveillance scans in DLBCL. J. Clin. Oncol. 31(15), Abstract 8504 (2013).
55. Morschhauser F, Recher C, Milpied N et al. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter Phase II study in patients with follicular lymphoma. Ann. Oncol. 23, 2687-2695 (2012).
56. Ladetto M, Lobetti-Bodoni C, Mantoan B et al. Minimal residual disease independently predicts outcome in follicula lymphoma patients treated with rituximab-intensive non-ASCT-based programs: results of the ML17638 trial of the Fondazione Italiana Linfomi (FIL). Blood 118(21), Abstract 787 (2012).
57. Hirt C, Schuler F, Kiefer T et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br. J. Haematol. 141, 631-640 (2008).
58. van Oers MH, Tonnissen E, Van Glabbeke M et al. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 Phase III intergroup study. J. Clin. Oncol. 28, 2246-2252 (2010).
59. Warren JL, Klabunde CN, Schrag D et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med. Care 40(8 Suppl.), IV-3-18 (2002).
60. Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer 116, 3843-3851 (2010).
61. Federico M, Bellei M, Marcheselli L et al. Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project J. Clin. Oncol. 27(27), 4555-4562 (2009).
62. Solal-Celigny P, Bellei M, Marcheselli L et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J. Clin. Oncol. 30, 3848-3853 (2012).
63. Friedberg JW, Byrtek M, Link BK et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J. Clin. Oncol. 30, 3368-3375 (2012).
64. Nooka AK, Nabhan C, Zhou X et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann. Oncol. 24, 441-448 (2013).
65. Nabhan C, Byrtek M, Taylor MD et al. Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study. Cancer 118, 4842-4850 (2012).
66. Martin P, Link BK, Byrtek M et al. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study. Cancer 119(23), 4129-4136 (2013).
67. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453-1457 (2007).
68. Murphy MK, Black NA, Lamping DL et al. Consensus development methods, and their use in clinical guideline development. Health Technol. Assess 2, i-iv, 1-88 (1998).
69. Dolan JG. Shared decision-making -transferring research into practice: the Analytic Hierarchy Process (AHP). Patient Educ. Couns. 73, 418-425 (2008).
70. Committee on Comparative Effectiveness Research Prioritization, Board on Health Care Services, Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research (2009). www.iom.edu/Reports/2009/ ComparativeEffectivenessResearchPriorities. aspx (Accessed 12 November 2013)
71. ClinicalTrials.gov: maintenance therapy for follicular lymphoma. http://clinicaltrial.gov/ct2/results?term=Mai ntenance+treatment+AND+Follicular+Lump homa (Accessed 10 June 2013)
72. Translational Research Program. Lymphoma SPOREs. http://trp.cancer.gov/ spores/lymphoma.htm (Accessed 13 July 2013)